Switching from semaglutide to tirzepatide is a prescribing decision, not a dose conversion. There is no validated milligram equivalence between the two molecules; the labeled tirzepatide starting dose is 2.5 mg weekly, while a prospective study directly switched selected adults with type 2 diabetes from stable GLP-1 therapy to 5 mg, so the prescriber sets the starting dose and timing. The first tirzepatide injection normally takes the place of the semaglutide dose that would have been due that week. Gastrointestinal effects tend to reset along with the dose. And it takes a new prescription, because these are two different medicines with different receptor targets — not two strengths of the same one.

If the open question is which of the two suits you better, tirzepatide versus semaglutide covers that comparison. This article is about the mechanics of the change. If instead the question is whether the two can run at the same time, semaglutide and tirzepatide together explains why the answer is usually no.

Why a prescriber changes agent

A switch is rarely the first thing tried. The semaglutide labeling builds that in: if a dose is not tolerated during escalation, prescribers are told to consider delaying the increase by four weeks rather than abandoning the drug. A change of agent comes after that.

What does lead to one:

  • Tolerability that never settles. Nausea, reflux or constipation that persists at a dose someone needs to stay on.
  • Response has stalled. Weight or HbA1c stops moving at a maintenance dose, and further escalation is either unavailable or not tolerated. SURPASS-SWITCH enrolled exactly this population — adults with type 2 diabetes whose HbA1c sat between 7.0% and 9.5% on a stable weekly dose.
  • A different mechanism. Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts at two receptors, GIP and GLP-1, which is why the change is not simply a stronger version of the same drug.
  • Practical constraints. What a plan covers, what a pharmacy can supply, and what the month costs.

There is no validated dose conversion

Anyone converting semaglutide milligrams into tirzepatide milligrams on a chart found online is guessing, and it is not a small guess.

Semaglutide's injectable maintenance doses sit at 1.7 mg and 2.4 mg weekly, with a 7.2 mg ceiling on the current label; tirzepatide's are 5 mg, 10 mg and 15 mg. The scales were never built to line up — different peptides, different receptor targets, different potencies at them.

The pharmacokinetics differ too. Semaglutide has a half-life of about seven days and reaches steady state after four to five weeks of weekly dosing (Hall et al., Clin Pharmacokinet 2018). Tirzepatide's half-life is roughly five days in a population model pooling nineteen studies (Schneck and Urva, CPT Pharmacometrics Syst Pharmacol 2024), and the current Zepbound labeling gives approximately five to six days.

Most telling, neither label contains a conversion. The tirzepatide labeling offers no adjusted starting dose for people arriving from another GLP-1 receptor agonist, and the semaglutide labeling offers no switching guidance beyond stating that concomitant use with another agonist is not recommended. Where two manufacturers declined to publish an equivalence, a chart on a forum has not found one.

Tirzepatide restarts at its own starting dose

The labeled starting dosage of tirzepatide is 2.5 mg once weekly for four weeks, and the label states plainly that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage. Increases go in 2.5 mg steps after at least four weeks at the current dose, to a maximum of 15 mg once weekly. Nothing in that schedule changes because a patient arrives from semaglutide.

The randomized evidence follows the same rule. In SURPASS-SWITCH, 282 adults with type 2 diabetes on a stable dulaglutide dose for at least six months were assigned either to escalate it or to move to tirzepatide; the tirzepatide arm began at 2.5 mg weekly and stepped up by 2.5 mg every four weeks. At week 40, HbA1c had fallen 1.44% on tirzepatide against 0.67% on escalated dulaglutide, and weight 10.5 kg against 3.6 kg (Billings et al., Ann Intern Med 2025). Worth naming honestly: that trial moved people off dulaglutide, not semaglutide. It is the best randomized switch data available and it is not a study of this exact question.

Starting higher has been studied. A prospective study moved adults on stable GLP-1 receptor agonist therapy — 55% of them on semaglutide at 0.5, 1.0 or 2.0 mg — directly onto tirzepatide 5 mg, with HbA1c down 0.43% and weight down 2.15 kg at twelve weeks (Jabbour et al., Endocr Pract 2024). That is a judgement a prescriber makes with the full history in front of them, not a shortcut to apply alone. The tirzepatide dosage schedule sets out the standard ladder.

Timing the first dose

Both medicines are weekly, which makes the handover simple in principle: the new injection goes where the old one would have gone.

No drug-free washout is built into the trial protocols. SURPASS-SWITCH participants moved across around the time their next injection was due, and the prospective study above describes a direct change rather than a gap. The labeling says only that semaglutide is not used concomitantly with another GLP-1 receptor agonist — the two do not run alongside each other, which is different from requiring a long gap.

Exposure overlaps anyway, because semaglutide does not vanish on the day it stops. At a seven-day half-life it takes roughly five weeks to clear, which how long semaglutide stays in your system covers in detail. That residual exposure is one more reason the new medicine starts at the bottom of its own ladder, and the date of the first dose is set by the prescriber who writes it.

What happens to side effects when switching from semaglutide to tirzepatide

Gastrointestinal effects dominate both drugs. In SURPASS-SWITCH the most common treatment-emergent adverse events were nausea and diarrhea, and serious adverse events were reported by 7.2% of the tirzepatide group against 7.0% of the dulaglutide group. In the prospective direct-switch study, 13.2% of participants developed a gastrointestinal event over twelve weeks and 2% stopped tirzepatide because of an adverse event.

Two things tend to work in a switcher's favor. Restarting low re-runs the gentlest part of the escalation, and prior GLP-1 exposure means the gut has already adapted to delayed gastric emptying once. Neither makes an easy switch certain; some people tolerate one molecule better than the other for reasons nobody can predict.

Two things need attention. If semaglutide was taken alongside insulin or a sulfonylurea, the hypoglycemia picture changes when the agent changes, and those doses are the prescriber's to review. And a symptom blamed on semaglutide that never resolved deserves a second look, not reassignment to the new drug. Tirzepatide side effects covers the full profile.

What a new intake asks

A switch is a new prescription for a different medicine, so it runs through the same review as a first request rather than an amendment to an existing one. A provider licensed in your state reads the history and decides.

The questionnaire covers personal or family history of medullary thyroid carcinoma or MEN2, which rules out both agents; pancreatitis, gallbladder disease and diabetic retinopathy; every current medication, with insulin and sulfonylureas flagged specifically; pregnancy or breastfeeding; and the semaglutide history itself — the dose, how long it was held there, and which effects appeared and when. That last part tells a prescriber whether a change of molecule is a reasonable next step or whether the current one has not yet had a fair run.

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved, and compounded medications are not reviewed by the FDA for safety, effectiveness or quality. A licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.

A licensed provider reviews every request and prescribes only when it is right for you. Not everyone qualifies, and asking to switch is a real question with a real answer either way.